A Study to Evaluate ICP-022 in Patients With R/R PCNSL and SCNSL

A Study of CD19/22 CART Cells Combined With PD-1 Inhibitor in Relapsed/Refractory B-cell Lymphoma

NCT04539444 ·Status: UNKNOWN ·Phase: PHASE2

Clinical Trial of IL - 22BP Safety, Tolerability, and Antitumor Activity in Refractory Solid Tumors.

NCT07040943 ·Status: RECRUITING ·Phase: PHASE1

IASO206 in Patients With Relapsed/Refractory Multiple Myeloma

NCT07322159 ·Status: NOT_YET_RECRUITING ·Phase: EARLY_PHASE1

Safety and Efficiency Study of CD19-PD1-CART Cell in Relapsed/Refractory B Cell Lymphoma

NCT04163302 ·Status: UNKNOWN ·Phase: PHASE2

A Phase I Clinical Study of JS004 in Subjects With Recurrent/Refractory Malignant Lymphoma of China

NCT04477772 ·Status: COMPLETED ·Phase: PHASE1

A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- NHL

NCT04412174 ·Status: UNKNOWN ·Phase: EARLY_PHASE1

A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of NEUK203-215 Injection in Adult Chinese Patients With Relapsed/Refractory Autoimmune Diseases

NCT07144462 ·Status: RECRUITING ·Phase: EARLY_PHASE1

An Exploratory Clinical Study Evaluating the Safety and Efficacy of Intravenous Anti-CD20/CD30-CAR-T Cell Infusion in Relapsed/Refractory Lymphoma Patients.

NCT06519344 ·Status: NOT_YET_RECRUITING ·Phase: EARLY_PHASE1

Anti-CD5 CAR T Cells for Relapsed/Refractory T Cell Malignancies

NCT04594135 ·Status: UNKNOWN ·Phase: PHASE1

Clinical Study of SL19+22 CAR-T Cells for Relapsed or Refractory Non-Hodgkin Lymphoma

NCT05206071 ·Status: UNKNOWN ·Phase: NA

Safety and Efficacy Study of CD22 CAR-T Cells for Relapsed or Refractory Acute Lymphoblastic Leukemia

NCT04546906 ·Status: UNKNOWN ·Phase: NA

A Study of CM336 in Patients With Relapsed or Refractory Multiple Myeloma

NCT05299424 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

LCAR-F33S in Treatment of Relapsed/Refractory Multiple Myeloma

NCT07100067 ·Status: RECRUITING ·Phase: NA

Clinical Study of CAR-iNKT Cells in the Treatment of Relapsed/Refractory/High-risk B-cell Tumors

NCT04814004 ·Status: UNKNOWN ·Phase: PHASE1

Study of Anti-CD19/CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma

NCT03824964 ·Status: UNKNOWN ·Phase: EARLY_PHASE1

Study of IFN-α Combined With CAR-T Cell Therapy in Relapsed and Refractory Acute Lymphoblastic Leukemia（R/R-ALL）

NCT04534634 ·Status: UNKNOWN ·Phase: PHASE2

Study of Targeted CD22/CD19 CAR-T Therapy for First-line Consolidation of B-cell Lymphoma

NCT07094477 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

CD5 CAR T-Cell Therapy for r/r T-cell Lymphomas

NCT07022964 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

To Assess Safety, Tolerability, and Efficacy of Anti-GPRC5D-CD19-CAR-T in Relapsed/Refractory Multiple Myeloma

NCT06298266 ·Status: NOT_YET_RECRUITING ·Phase: EARLY_PHASE1

A Study of CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Central Nervous System Hematological Malignancies

NCT04532203 ·Status: RECRUITING ·Phase: EARLY_PHASE1

Study to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Mantle Cell Lymphoma

NCT05155215 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

Clinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT05768529 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Clinical Trial of SL1904B CAR-T Cells for Relapsed or Refractory Non-Hodgkin Lymphoma

NCT04447547 ·Status: UNKNOWN ·Phase: NA

Study of Anti-CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma

NCT03692767 ·Status: UNKNOWN ·Phase: EARLY_PHASE1

Anti-CD33 CAR-T Cells for the Treatment of Relapsed/Refractory CD33+ Acute Myeloid Leukemia

NCT05445765 ·Status: UNKNOWN ·Phase: PHASE1